Biotech News
Related news
MNKDMannKind2026-10-29 20:01 EST
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
MNKDMannKind2026-08-05 20:01 EST
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
CVRXCVRx2026-07-23 20:30 EST
CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026
MLYSMineralys Therapeutics2026-08-04 12:00 EST
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
CVRXCVRx2026-10-22 20:30 EST
CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026
ALTAltimmune2026-08-05 12:00 EST
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
MLYSMineralys Therapeutics2026-10-28 20:05 EST
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
BLTEBelite Bio2026-08-06 12:00 EST
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
LXRXLexicon Pharmaceuticals2026-07-30 12:30 EST
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
RYTMRhythm Pharmaceuticals2026-07-21 12:00 EST
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
MannKind
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...
Recent company news
MNKDMannKind2026-11-10 13:00 EST
MannKind to Participate in Upcoming Investor Conferences
MNKDMannKind2026-11-05 21:01 EST
MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update
MNKDMannKind2026-10-29 20:01 EST
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
MNKDMannKind2026-10-14 20:01 EST
MannKind to Participate in the Chardan Healthcare Conference
MNKDMannKind2026-10-10 00:00 EST
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
Stock data
- Close
- 3.95 USD
- Market cap
- 1.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
